查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
裘馨氏肌肉萎縮症治療藥的全球市場
市場調查報告書
商品編碼
1199073

裘馨氏肌肉萎縮症治療藥的全球市場

Duchenne Muscular Dystrophy Drugs
出版日期: | 出版商: Global Industry Analysts, Inc. | 英文 196 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

簡介目錄

全球裘馨氏肌肉萎縮症治療藥的市場規模預測將從2022年的11億美元到2030年達到181億美元，在分析期間的2022年～2030年預計將以年複合成長率42.5％的速度成長。

本報告提供全球裘馨氏肌肉萎縮症治療藥市場相關調查分析，提供市場趨勢與促進因素，地區分析，競爭情形等資訊。

調查對象企業範例(全46公司):

  • Acceleron Pharma, Inc.
  • Akashi Therapeutics, Inc.
  • BioMarin Pharmaceutical, Inc.
  • Bristol-Myers Squibb Company
  • Eli Lilly and Company
  • Janssen Pharmaceuticals, Inc.
  • Lexicon Pharmaceuticals, Inc.
  • Nippon Shokubai Co., Ltd.
  • Nobelpharma Co., Ltd.
  • Pfizer, Inc.
  • PTC Therapeutics, Inc.
  • Sarepta Therapeutics Inc.
  • Taiho Pharmaceutical Co., Ltd.

目錄

第1章 調查手法

第2章 摘要整理

  • 市場概要
  • 主要企業
  • 市場趨勢與促進因素
  • 全球市場預測

第3章 市場分析

  • 美國
  • 加拿大
  • 日本
  • 中國
  • 歐洲
  • 法國
  • 德國
  • 義大利
  • 英國
  • 其他的歐洲
  • 亞太地區
  • 其他地區

第4章 競爭

簡介目錄
Product Code: MCP11652

What`s New for 2023?

»Special coverage on Russia-Ukraine war; global inflation; easing of "zero-Covid" policy in China and its `bumpy` reopening; supply chain disruptions, global trade tensions; and risk of recession.

»Global competitiveness and key competitor percentage market shares

» Market presence across multiple geographies - Strong/Active/Niche/Trivial

»Online interactive peer-to-peer collaborative bespoke updates

»Access to our digital archives and MarketGlass Research Platform

»Complimentary updates for one year

Looking Ahead to 2023

The global economy is at a critical crossroads with a number of interlocking challenges and crises running in parallel. The uncertainty around how Russia`s war on Ukraine will play out this year and the war`s role in creating global instability means that the trouble on the inflation front is not over yet. Food and fuel inflation will remain a persistent economic problem. Higher retail inflation will impact consumer confidence and spending. As governments combat inflation by raising interest rates, new job creation will slowdown and impact economic activity and growth. Lower capital expenditure is in the offing as companies go slow on investments, held back by inflation worries and weaker demand. With slower growth and high inflation, developed markets seem primed to enter into a recession. Fears of new COVID outbreaks and China's already uncertain post-pandemic path poses a real risk of the world experiencing more acute supply chain pain and manufacturing disruptions this year. Volatile financial markets, growing trade tensions, stricter regulatory environment and pressure to mainstream climate change into economic decisions will compound the complexity of challenges faced. Year 2023 is expected to be tough year for most markets, investors and consumers. Nevertheless, there is always opportunity for businesses and their leaders who can chart a path forward with resilience and adaptability.

Global Duchenne Muscular Dystrophy Drugs Market to Reach $18.1 Billion by 2030

In the changed post COVID-19 business landscape, the global market for Duchenne Muscular Dystrophy Drugs estimated at US$1.1 Billion in the year 2022, is projected to reach a revised size of US$18.1 Billion by 2030, growing at a CAGR of 42.5% over the analysis period 2022-2030. Exon Skipping, one of the segments analyzed in the report, is projected to record a 48.6% CAGR and reach US$12.8 Billion by the end of the analysis period. Taking into account the ongoing post pandemic recovery, growth in the Steroid Therapy segment is readjusted to a revised 32% CAGR for the next 8-year period.

The U.S. Market is Estimated at $312.7 Million, While China is Forecast to Grow at 40% CAGR

The Duchenne Muscular Dystrophy Drugs market in the U.S. is estimated at US$312.7 Million in the year 2022. China, the world`s second largest economy, is forecast to reach a projected market size of US$2.8 Billion by the year 2030 trailing a CAGR of 40% over the analysis period 2022 to 2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at 39.3% and 35.7% respectively over the 2022-2030 period. Within Europe, Germany is forecast to grow at approximately 28.5% CAGR.

Select Competitors (Total 46 Featured):

  • Acceleron Pharma, Inc.
  • Akashi Therapeutics, Inc.
  • BioMarin Pharmaceutical, Inc.
  • Bristol-Myers Squibb Company
  • Eli Lilly and Company
  • Janssen Pharmaceuticals, Inc.
  • Lexicon Pharmaceuticals, Inc.
  • Nippon Shokubai Co., Ltd.
  • Nobelpharma Co., Ltd.
  • Pfizer, Inc.
  • PTC Therapeutics, Inc.
  • Sarepta Therapeutics Inc.
  • Taiho Pharmaceutical Co., Ltd.

TABLE OF CONTENTS

I. METHODOLOGY

II. EXECUTIVE SUMMARY

  • 1. MARKET OVERVIEW
    • Influencer Market Insights
    • World Market Trajectories
    • Duchenne Muscular Dystrophy (DMD) Drugs Market To Exhibit Strong Growth
    • Duchenne Muscular Dystrophy Drugs - Global Key Competitors Percentage Market Share in 2022 (E)
    • Competitive Market Presence - Strong/Active/Niche/Trivial for Players Worldwide in 2022 (E)
    • Impact of Covid-19 and a Looming Global Recession
    • Global Market Dynamics
    • Treatment Overview and Recent Developments
    • Steroids used for the Treatment of DMD
    • Translarna Exhibits Positive Result in Children with DMD
    • Clinical Trials Depict Emflaza Preserves Motor Function Better than Corticosteroids
    • Trial Shows Golodirsen Increases Dystrophin Production in DMD Patients
    • Casimersen and Golodirsen Exhibits Positive Results in Sarepta's ESSENCE study
    • EXONDYS 51® Drug Details
    • FDA Approves Corticosteroid Emflaza for Treating DMD Patients
  • 2. FOCUS ON SELECT PLAYERS
  • 3. MARKET TRENDS & DRIVERS
    • Pipeline Analysis
    • Drug Price Details: Exondys51
    • Sarepta's DMD Gene Therapy Trial Update
  • 4. GLOBAL MARKET PERSPECTIVE
    • TABLE 1: World Recent Past, Current & Future Analysis for Duchenne Muscular Dystrophy Drugs by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2022 through 2030 and % CAGR
    • TABLE 2: World 8-Year Perspective for Duchenne Muscular Dystrophy Drugs by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets for Years 2023 & 2030
    • TABLE 3: World Recent Past, Current & Future Analysis for Mutation Suppression by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2022 through 2030 and % CAGR
    • TABLE 4: World 8-Year Perspective for Mutation Suppression by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2023 & 2030
    • TABLE 5: World Recent Past, Current & Future Analysis for Exon Skipping by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2022 through 2030 and % CAGR
    • TABLE 6: World 8-Year Perspective for Exon Skipping by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2023 & 2030
    • TABLE 7: World Recent Past, Current & Future Analysis for Other Segments by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2022 through 2030 and % CAGR
    • TABLE 8: World 8-Year Perspective for Other Segments by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2023 & 2030
    • TABLE 9: World Duchenne Muscular Dystrophy Drugs Market Analysis of Annual Sales in US$ Thousand for Years 2014 through 2030
    • TABLE 10: World Recent Past, Current & Future Analysis for Steroid Therapy by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2022 through 2030 and % CAGR
    • TABLE 11: World 8-Year Perspective for Steroid Therapy by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2023 & 2030

III. MARKET ANALYSIS

  • UNITED STATES
    • Duchenne Muscular Dystrophy Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United States for 2023 (E)
    • TABLE 12: USA Recent Past, Current & Future Analysis for Duchenne Muscular Dystrophy Drugs by Segment - Exon Skipping, Steroid Therapy, Mutation Suppression and Other Segments - Independent Analysis of Annual Sales in US$ Thousand for the Years 2022 through 2030 and % CAGR
    • TABLE 13: USA 8-Year Perspective for Duchenne Muscular Dystrophy Drugs by Segment - Percentage Breakdown of Value Sales for Exon Skipping, Steroid Therapy, Mutation Suppression and Other Segments for the Years 2023 & 2030
  • CANADA
    • TABLE 14: Canada Recent Past, Current & Future Analysis for Duchenne Muscular Dystrophy Drugs by Segment - Exon Skipping, Steroid Therapy, Mutation Suppression and Other Segments - Independent Analysis of Annual Sales in US$ Thousand for the Years 2022 through 2030 and % CAGR
    • TABLE 15: Canada 8-Year Perspective for Duchenne Muscular Dystrophy Drugs by Segment - Percentage Breakdown of Value Sales for Exon Skipping, Steroid Therapy, Mutation Suppression and Other Segments for the Years 2023 & 2030
  • JAPAN
    • Duchenne Muscular Dystrophy Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Japan for 2023 (E)
    • TABLE 16: Japan Recent Past, Current & Future Analysis for Duchenne Muscular Dystrophy Drugs by Segment - Exon Skipping, Steroid Therapy, Mutation Suppression and Other Segments - Independent Analysis of Annual Sales in US$ Thousand for the Years 2022 through 2030 and % CAGR
    • TABLE 17: Japan 8-Year Perspective for Duchenne Muscular Dystrophy Drugs by Segment - Percentage Breakdown of Value Sales for Exon Skipping, Steroid Therapy, Mutation Suppression and Other Segments for the Years 2023 & 2030
  • CHINA
    • Duchenne Muscular Dystrophy Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in China for 2023 (E)
    • TABLE 18: China Recent Past, Current & Future Analysis for Duchenne Muscular Dystrophy Drugs by Segment - Exon Skipping, Steroid Therapy, Mutation Suppression and Other Segments - Independent Analysis of Annual Sales in US$ Thousand for the Years 2022 through 2030 and % CAGR
    • TABLE 19: China 8-Year Perspective for Duchenne Muscular Dystrophy Drugs by Segment - Percentage Breakdown of Value Sales for Exon Skipping, Steroid Therapy, Mutation Suppression and Other Segments for the Years 2023 & 2030
  • EUROPE
    • Duchenne Muscular Dystrophy Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Europe for 2023 (E)
    • Irish Boys with nonsense mutation Duchenne muscular dystrophy (nmDMD) Gains Access to Key, Life-Supporting Drug
    • CHMP Rejects Exondys 51 in Europe
    • TABLE 20: Europe Recent Past, Current & Future Analysis for Duchenne Muscular Dystrophy Drugs by Geographic Region - France, Germany, Italy, UK and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2022 through 2030 and % CAGR
    • TABLE 21: Europe 8-Year Perspective for Duchenne Muscular Dystrophy Drugs by Geographic Region - Percentage Breakdown of Value Sales for France, Germany, Italy, UK and Rest of Europe Markets for Years 2023 & 2030
    • TABLE 22: Europe Recent Past, Current & Future Analysis for Duchenne Muscular Dystrophy Drugs by Segment - Exon Skipping, Steroid Therapy, Mutation Suppression and Other Segments - Independent Analysis of Annual Sales in US$ Thousand for the Years 2022 through 2030 and % CAGR
    • TABLE 23: Europe 8-Year Perspective for Duchenne Muscular Dystrophy Drugs by Segment - Percentage Breakdown of Value Sales for Exon Skipping, Steroid Therapy, Mutation Suppression and Other Segments for the Years 2023 & 2030
  • FRANCE
    • Duchenne Muscular Dystrophy Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in France for 2023 (E)
    • TABLE 24: France Recent Past, Current & Future Analysis for Duchenne Muscular Dystrophy Drugs by Segment - Exon Skipping, Steroid Therapy, Mutation Suppression and Other Segments - Independent Analysis of Annual Sales in US$ Thousand for the Years 2022 through 2030 and % CAGR
    • TABLE 25: France 8-Year Perspective for Duchenne Muscular Dystrophy Drugs by Segment - Percentage Breakdown of Value Sales for Exon Skipping, Steroid Therapy, Mutation Suppression and Other Segments for the Years 2023 & 2030
  • GERMANY
    • Duchenne Muscular Dystrophy Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Germany for 2023 (E)
    • TABLE 26: Germany Recent Past, Current & Future Analysis for Duchenne Muscular Dystrophy Drugs by Segment - Exon Skipping, Steroid Therapy, Mutation Suppression and Other Segments - Independent Analysis of Annual Sales in US$ Thousand for the Years 2022 through 2030 and % CAGR
    • TABLE 27: Germany 8-Year Perspective for Duchenne Muscular Dystrophy Drugs by Segment - Percentage Breakdown of Value Sales for Exon Skipping, Steroid Therapy, Mutation Suppression and Other Segments for the Years 2023 & 2030
  • ITALY
    • TABLE 28: Italy Recent Past, Current & Future Analysis for Duchenne Muscular Dystrophy Drugs by Segment - Exon Skipping, Steroid Therapy, Mutation Suppression and Other Segments - Independent Analysis of Annual Sales in US$ Thousand for the Years 2022 through 2030 and % CAGR
    • TABLE 29: Italy 8-Year Perspective for Duchenne Muscular Dystrophy Drugs by Segment - Percentage Breakdown of Value Sales for Exon Skipping, Steroid Therapy, Mutation Suppression and Other Segments for the Years 2023 & 2030
  • UNITED KINGDOM
    • Duchenne Muscular Dystrophy Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United Kingdom for 2023 (E)
    • TABLE 30: UK Recent Past, Current & Future Analysis for Duchenne Muscular Dystrophy Drugs by Segment - Exon Skipping, Steroid Therapy, Mutation Suppression and Other Segments - Independent Analysis of Annual Sales in US$ Thousand for the Years 2022 through 2030 and % CAGR
    • TABLE 31: UK 8-Year Perspective for Duchenne Muscular Dystrophy Drugs by Segment - Percentage Breakdown of Value Sales for Exon Skipping, Steroid Therapy, Mutation Suppression and Other Segments for the Years 2023 & 2030
  • REST OF EUROPE
    • TABLE 32: Rest of Europe Recent Past, Current & Future Analysis for Duchenne Muscular Dystrophy Drugs by Segment - Exon Skipping, Steroid Therapy, Mutation Suppression and Other Segments - Independent Analysis of Annual Sales in US$ Thousand for the Years 2022 through 2030 and % CAGR
    • TABLE 33: Rest of Europe 8-Year Perspective for Duchenne Muscular Dystrophy Drugs by Segment - Percentage Breakdown of Value Sales for Exon Skipping, Steroid Therapy, Mutation Suppression and Other Segments for the Years 2023 & 2030
  • ASIA-PACIFIC
    • Duchenne Muscular Dystrophy Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Asia-Pacific for 2023 (E)
    • TABLE 34: Asia-Pacific Recent Past, Current & Future Analysis for Duchenne Muscular Dystrophy Drugs by Segment - Exon Skipping, Steroid Therapy, Mutation Suppression and Other Segments - Independent Analysis of Annual Sales in US$ Thousand for the Years 2022 through 2030 and % CAGR
    • TABLE 35: Asia-Pacific 8-Year Perspective for Duchenne Muscular Dystrophy Drugs by Segment - Percentage Breakdown of Value Sales for Exon Skipping, Steroid Therapy, Mutation Suppression and Other Segments for the Years 2023 & 2030
  • REST OF WORLD
    • TABLE 36: Rest of World Recent Past, Current & Future Analysis for Duchenne Muscular Dystrophy Drugs by Segment - Exon Skipping, Steroid Therapy, Mutation Suppression and Other Segments - Independent Analysis of Annual Sales in US$ Thousand for the Years 2022 through 2030 and % CAGR
    • TABLE 37: Rest of World 8-Year Perspective for Duchenne Muscular Dystrophy Drugs by Segment - Percentage Breakdown of Value Sales for Exon Skipping, Steroid Therapy, Mutation Suppression and Other Segments for the Years 2023 & 2030

IV. COMPETITION